The September 21, 2017 amendments to the Patented Medicines (Notice of Compliance) Regulations (see our article here) introduced a new scheme for pharmaceutical patent linkage litigation in Canada. That scheme is now much closer to the US Hatch-Waxman scheme, but with remaining key differences, as shown in the chart below. A special thank you to Brian Coggio of Fish & Richardson for contributing the Hatch-Waxman details.

*revised July 2022.
Related Publications & Articles
-
Federal Court of Appeal dismisses appeal challenging amended basket of comparator countries in PMPRB Regulations
On December 5, 2022, the Federal Court of Appeal (FCA) dismissed Innovative Medicines Canada (IMC) and sixteen innovative pharmaceutical companies’ appeal.Read More -
2022 Highlights in Canadian Life Sciences IP and Regulatory Law
2022 Highlights in Canadian Life Sciences IP and Regulatory Law.Read More -